Prime Medicine, Inc. faces risks in the gene editing sector despite positive developments, caution advised for retail investors. Click for my PRME stock update.

Editas Medicine has decided to end the development of its gene-editing therapy for thalassaemia and sickle cell disease (SCD), narrowing its R&D focus and making sweeping cuts to its workforce.

CRISPR & Cas Genes Market Growing funding in gene therapy worldwide is a prominent factor driving the CRISPR & Cas genes market.

TD Cowen analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

Saint Louis University's School of Medicine has a long tradition of excellence in medical school, graduate medical education and graduate education. Established in 1836, the school has the distinction ...

Their reputation was well deserved, for the study and practice of medicine was then led by Muslim societies across their immense territory, which extended from modern-day southern Spain to Iran.

After hours: February 3 at 6:27:52 PM EST Loading Chart for PRME ...

Forcing a struggling child to take any medicine can lead to vomiting or choking. Using a better technique can sometimes get rid of the child's resistance. Doctors can sometimes replace a bad-tasting ...